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INTRODUCTION 
            According to American college of cardiology, the definition of 
myocardial infarction is elevation of cardiac enzymes (CK-MB, 
TROPONIN I, TROPONIN T) in the presence of  symptoms(chest pain, 
palpitation, sweating or angina equivalents)  with evidence of MI by ECG 
or ECHO.
1
Compared to Creatinine kinase , Troponins are highly specific 
for myocardial injury. By using third generation immunoassays, troponins 
have high sensitivity in detection of ischaemia.  Hence, besides  MI  there 
are some acute conditions with elevated troponins like  tachyarrhythmias,  
acute cerebrovascular accident,  acute pulmonary  thromboembolism,  
chronic kidney disease, septic shock, myocardial injury . But whatever 
the pathogenetic mechanism which leads to release of enzymes from 
myocyte, the elevated enzyme levels  always indicates   a poor prognosis 
in these  cases
4
 
Paroxysmal supraventricular tachycardia
5
 (PSVT), a commonest 
form arrhythmia  seen in the  emergency department. Compared to 
ventricular tachyarrhythmias these patients are hemodynamically stable 
and they have good prognosis on treatment. Serum cardiac troponin I
6
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(cTnI)  testing provides important risk stratification in these group of 
arrhythmias.
5
 
In a retrospective study conducted by Calberg et al, he studied 51 
PSVT patients
7
 who were identified on the basis of  INTERNATIONAL 
CLASSIFICATION OF DISEASES , NINTH EDITION codes. Fifty one 
were included in the data analysis. They had atleast one serum cTn value 
measured. Among them 11 had positive values (0.04 ng/ml)
8
. Six weeks 
outcome for these patients were studied. The results were  one had 
recurrence, no deaths and moreover cTn I  testing didn’t  identify  PSVT  
patients at risk of worse prognosis
9
. 
Hence the recommendation of this investigation in PSVT patients 
needs to be studied in a large basis to ascertain it’s importance in 
assessing the risk in these group of patients. 
10 
Hence to test the hypothesis and to identify the association  
between the cardiac troponins and the non coronary  SVT and its impact 
on the prognosis of the patient ,this study  was  conducted  in our hospital 
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REVIEW OF LITERATURE 
CARDIAC TROPONINS 
The troponins are the proteins present in the myocyte. The troponin 
present in cardiac muscle is different from the troponin present in skeletal 
muscle. 
        The troponin   in the cardiac myocyte consists of three units  C,  I, 
T
11
  and  is located  on the  thin (actin) filament of striated (cardiac) 
muscle.  Troponin is a component of actin filaments alon g 
with actin and tropomyosin
12
. When calcium attaches to Troponin 
C, tropomyosin  moves and exposes the active site of actin filaments, so 
that myosin  head can attach to the actin and produce  contraction of 
myocyte with utilization of ATP. When the calcium is absent, 
tropomyosin attaches with  the active site of Actin, so that myosin can’t  
contact  with Actin. 
Hence contraction is prevented. It has  been shown in some studies 
that troponin I found to inhibit angiogenesis 
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The functions of various subunits are 
Troponin C binds to calcium ions to produce a conformational 
change in TnI so that Tropomyosin inhibition is removed
12 
Troponin T  binds to tropomyosin,  to form a troponin- 
Tropomyosin complex
13
      
Troponin I   binds to actin in  myofilaments  to hold the troponin-   
tropomyosin complex in place
14 
Smooth muscle does not have troponin. 
The cardiac isoforms of troponin T and I are only expressed in 
cardiac muscle. Hence, they  are more specific than     creatine kinase 
(CK)  for myocardial   injury
15 
Cardiac troponin I  - it’s  molecular weight  is 23KDa16 and it’s 
electron microscopic structure is 3 dimensional with ribbon like pattern. 
It’s made up of 209 amino acid  residues. The theoretical pI of cTnI is 
9.87
17
. The amino acid in 22 and 23 position are serines. In vivo these 
amino acids can be phosphorylated by protein kinases, so  we can see 
four forms of protein – onedephospho, two monophospho and one 
bisphospho  within the cell. These biochemical Phosphorylation  of  
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troponin changes the  structural conformation  of  these protein and 
modifies its interaction with other troponins  as well as it’s binding with 
anti-TnI antibodies.
18 
Cardiac troponin T is 35 kda protein 
 
FIG 1:   ELECTRON MICROSCOPY STRUCTURE OF 
TROPONIN I 
Cardiac troponins  were available  as both  bounded  proteins  
within  thick and thin filaments and as a free form within in the 
cytoplasm. These free forms constitutes  6–8% for cTnT and 3.5% for 
cTnI
19
.  Following myocardial necrosis, cTn  egress rapidly from the cell  
and will appear in blood after 2–4 hour and persists for  up to 10–21 days  
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for effective  diagnosis
20
. Further the detection  of   even minimal amount 
cardiac troponins  by immunoassays is easy now, and it becomes cost 
effective, and the results are  available readily, making  them ideal  
biomarkers of myocardial injury 
VARIOUS CAUSES OF ELEVATED TROPONINS AND IT’S 
PREVALENCE 
Various studies conducted previously in various countries have 
found causes for elevated troponin apart from ACS. In ACS  its  elevation 
should  hav 100% prevalence to define myocardial infarction. 
CARDIAC TROPONIN RELEASE UNRELATED TO ACS 
SEPTIC  SHOCK / SIRS 
 Sepsis or systemic inflammatory response syndrome (SIRS) 
contributes the major mortality group in intensive care units.The elevated 
cTnI  (0.1 ng/ml) have been detected in 30% to 80%
21
  of these cases in 
the acute phases. The cause for this significant elevation mainly due to 
the different etiology and multiple pathogenetic mechanism  activated in 
sepsis. Among  these  cases, significant coronary artery disease has been 
ruled out by doing various investigations. 
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The reason for the release of cTn from  myocardial cells might be a 
damage to the cell membrane caused by ischaemia, necrosis due to an 
oxygen supply–demand  mismatch  prevailing in the myocardium22. Due 
to fever and tachycardia the oxygen demand of the myocardium is 
increased whereas  oxygen supply of the myocardium is reduced due to 
systemic hypoxemia from respiratory insufficiency, microcirculatory 
dysfunction due to  lactic acidosis, hypotension . In addition,  there will 
be activation of local and systemic  inflammatory pathways  leads to 
pouring of cytokines esp. tumour necrosis factor α, interleukin 6 , as well 
as bacterial endotoxins (Lipopolysaccharides), which leads  to direct 
cytotoxic effects on myocardium and vascular endothelium
23
. 
Moreover, elevation of these proteins above normal limit  provide 
prognostic significance and  the extent of cTn elevation seems to 
correlate with the severity of the disease process. Ver Elst et al  clearly 
demonstrated that cTnI‐positivity  in the sepsis patients  was strongly 
associated with  LV‐dysfunction24. 78%  of cTnI  positive patients had 
LV dysfunction compared to 9% in cTnI‐negative patients25. cTnI 
values were found to correlate significantly with the degree of 
hypotension and APACHE II score in crically ill patients. 
13 
 
 
 
 
Spies and colleagues  et al studied 26 patients with sepsis, the 
group of patients with cTnT values  0.2 μ/l showed an increased 
mortality rate (83% )  compared to the group with cTnT values below this 
value( 38%).
26 
Pulmonary embolism 
Among 38 patients with Pulmonary thromboembolism, elevated 
cTnI values (> 0.4 ng/ml)
27
 were seen in 47% of cases and elevated 
cTnT(0.1 ng/ml) were seen in 38% of cases. Every one in two patients 
presenting with chest pain and breathlessness diagnosed as PE had 
elevated cardiac enzymes in their biochemical profile. The  reason for 
myocardial damage is excessive Right ventricular wall stress and strain 
due to sudden afterload increase to right ventricle due to elevated 
pulmonary pressure
28
. Other  reasons may be  reduced  right coronary 
perfusion, hypoxia from perfusion–ventilation mismatch in thrombosed 
areas, systemic hypotension. 
Studies which where done previously showing elevated troponins 
in PE  mainly concludes 2 facts. First the peak cardiac troponin values in 
these patients are in lower cut off values  and lasts only for shorter 
duration in blood. The second the brief appearance of this minimal 
amount of these troponins indicates only  reversible myocardial injury 
14 
 
 
 
 
compared to high and long lasting troponins in acute coronary 
syndrome
29
. 
 
FIG 2  : RELEASE OF CARDIAC ENZYMES FROM CYTOSOLIC 
POOL 
Acute and chronic heart failure 
Elevated cTn in heart failure (HF) indicates decreased left 
ventricular ejection fraction and correlate  well with the severity of  heart 
failure and prognosis
30
. The major pathogenesis were progressive 
myocyte loss due to wall tension created by high filling pressures. The co 
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existing features are renin –angiotensin- aldosterone axis activation, overt  
sympathetic activity ,activation of inflammatory pathway which 
contributes further to myocardial damage
31
. Sometimes wall tension will 
aggravate sub endocardial ischaemia leading on to severe chest pain 
which mimicks ACS. 
In patients with chronic stable HF, elevated cTnI values were 
found in 15–23%  of  cases (> 0.1 ng/ml).  For cTnT, values above  0.1 
ng/ml were reported in 10–15% of cases32. There was no difference 
between the ischaemic and non‐ischaemic group.  In acute HF, 52–55% 
had elevated cTnT values. The presence of cTn in  HF  predicts a worse 
prognosis compared to troponin negative ones
33
. Patients with increased 
troponin values have usually shown ECHO with lower ejection fractions, 
grade iii and grade iv HF (New York Heart Association functional class), 
and poorer  outcome. Serial measurements of cTn was mandatory in 
grade iii and grade iv heart failure as it  provides additional prognostic 
information. A decrease of cTn from the previous values  usually was 
associated with  improvement of symptoms,  left ventricular function  and 
ejection fraction while persistently elevated or rising troponin values 
indicates high mortality. 
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Strenuous exercise 
Following prolonged isometric exercise, there will be elevation of 
cardiac troponins which will be normalized within 24 hours.This  was 
different  from the elevation seen in ACS. several studies were done 
previously to rule out association  between the elevated enzymes and it’s 
prognostic significance. None of them establishes their relationship.   
Further studies are needed to clarify some inconsistencies in this area. 
Acute pericarditis/myocarditis 
Acute   pericarditis  is commonly diagnosed in patients  with acute 
chest pain with ECG  showing persistent  concave ST elevation.  The 
most confusing issue was the presence of elevated enzyme level which 
makes us to diagnose this as ACS. Although troponins are not present in 
the pericardium, cTnI was reported to be elevated in 32–50% of cases of 
pericarditis
34
, as a consequence of the involvement of the epicardium in 
the inflammatory process. 
In patients with acute myocarditis , the only significant finding in 
ECG was inappropriate sinus tachycardia with ST-T changes .cTnI 
concentrations have been found to be increased in 34% of patients. The 
coronary angiogram was done in certain group to rule out ACS. The gold 
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standard for diagnosis was endomyocardial biopsy which shows 
myocytolysis and lymphocytic infiltrates in myocytes. Even this was 
positive  only in 10% 0f cases.
35
  Hence elevated troponin values are 
more sensitive in diagnosis compared to other diagnostic modality 
Cardiotoxic chemotherapy 
The cardiotoxic side effects of chemotherapy were well known to 
all. The commonly known adverse effects following chemotherapy  noted 
are ischaemia, endomyocardial fibrosis, cardiomyopathy, pericarditis  and 
different types of arrhythmias  due to long QT syndrome36. So these 
patients are routinely investigated based on risk factors. Recent studies 
showed that  biochemical markers like natriuretic peptides, creatinine 
kinase, troponins are found elevated in subset of patients who are at risk 
of myocardial damage
37
 So their role in predicting myocardial damage 
needs evaluation   in future.  
External Current Cardioversion/Defibrillator Shocks 
Radiofrequency  ablation used in certain arrhythmias to cut the 
closed electrical circuits, causes an elevation of cTn in more than 90% of 
patients and is due to direct  myocardial injury
38
, but these  usually  have 
no prognostic utility. External current cardioversion (ECV) used in 
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cardiac arrest and asystole caused  small increase of cTnI and no 
increases of cTnT, especially when biphasic mode was used compared to 
monophasic mode
39
. Repetitive defibrillator shocks given in advanced  
life support procedures, polymorphic VT, VF are known to  cause release 
cTn into the blood. But diagnostic and prognostic significance was not 
made out till now.  
Infiltrative Disorders 
         In systemic amyloidosis, the presence of  cardiomyopathy  indicates 
worst prognosis.  Dispenzieri and colleagues studied 261 patients with 
amyloidosis. He showed  that the median survival of patients with 
elevated troponins was significantly  reduced
40
  (six  months  compared  
to  that of  patients  with normal   values (22  months).   
The main pathogenesis was extracellular amyloid deposition causes 
compression of myocytes with subsequent release of cytosolic pool of 
cTn
41
. In many patients, the effective  diagnosis of cardiac involvement is 
made incidentally by a positive troponin  values in  the absence of signs 
or symptoms of ACS. So it is mandatory to do troponin assays in all 
amylodosis patients with significant systemic involvement which will 
allow earlier detection of prognostically adverse cardiomyopathy.
42
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Post‐heart transplantation  
       Following  transplantation, the presence of  elevated  cTn indicates to 
the possibility of  allograft  rejection  apart from  cardiac failure. In 1998 
Dengler and colleagues found that cTnT values increased in direct 
proportion with the severity of graft rejection according to the ISHLT 
(International Society of Heart and Lung Transplantation) grading 
system
43
. In the patients with severe rejection (ISHLT grade 3 and 4), 
almost all patients showed  elevated cTnT values. Hence if cTnT was 
negative, significant rejection could be excluded with a specificity of 
92%
44
. Recently the investigation of choice for allograft rejection is 
endomyocardial biopsy.  If cardiac troponins are negative,  Rejection can 
be ruled out easily.
45
 
Myocardial contusion 
         In severe blunt injury chest, cardiac contusion contributes  3–56% 
of cases. Cardiac troponins were found to be significantly elevated in 15–
45% of patients
46
 with cardiac contusion. The absence of these markers in 
blood along with echocardiography, we can easily exclude major 
contusion in the heart except  in few cases. 
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RENAL FAILURE/END STAGE RENAL DISEASE 
Troponins in renal failure  with  ACS 
            In CKD patients with ACS, troponin values are elevated similar or 
just higher compared to ACS in non CKD patients. However, in patients 
with chronic kidney disease, cTn concentrations develop higher peak 
values and troponin remains  higher
47
  for longer duration (1 month). so 
repeated early measurements are needed to detect a acute  rise in the 
already raised baseline values which indicates an acute ischaemia or 
infarction. 
Troponins in asymptomatic renal failure patients 
Cardiovascular disease was the commonest cause of death in 
patients with ESRD, hence a clinically silent cardiac pathology can 
always underlie these troponin elevations48. Previous studies were 
analysed based on the prevalence and prognostic impact of cTn in 
patients with ESRD either on haemodialysis or renal replacement therapy. 
Both cTnT and cTnI are commonly increased in asymptomatic patients 
with ESRD, even when there is no suspected myocardial ischaemia
49
.  
This means they have elevated baseline values compared to non CKD 
patients. 
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      Using third generation assay for cTnT, up to 53% of haemodialysis 
patients had elevated cTnT values, while 19% of  patients showed 
elevated cTnI values.
50
 This finding led to significant therapeutic 
implication  that  cTnI would be a more sensitive  marker for myocardial 
ischaemia in patients with CKD  compared to cTnT
51
.  The significant 
discovery is that troponin I undergoes fragmentation, phosphorylation, 
oxidation  in CKD patients and was highly unstable so that they  are 
undetectable by using routine immunoassays.        
Several previous studies were analysed for this baseline elevation 
of cardiac troponins. The first possible explaination was re expression of 
these cardiac isoforms in skeletal muscle in CKD patients
52
. The other 
possible explainations are reduced renal clearance of troponin in CKD 
patients, possibly renal anemia which causes oxygen supply – demand  
mismatch.  Moreover troponins undergoes metabolism in the blood to 
form smaller 8 – 25 kD proteins which were easily eliminated by normal 
kidney53. But CKD patients  have decreased ability to remove this 
substances in blood leading to elevated baseline parameters in these 
patients. 
22 
 
 
 
 
           Several large observational studies have clearly shown that 
elevated concentrations of  cTnT in patients with ESRD are valuable, 
independent, short and long term predictors of cardiac death
54
. 
ENZYMES  IN   SUPRAVENTRICULAR TACCHYARRYTHMIAS 
TABLE 1 
Author, 
date and 
country 
Patient group 
Study type 
(level of 
evidence) 
Outcomes Key results 
Study 
Weaknesses 
Redfearn, et 
al.  
2005  
UK 
3 patients ages 
22-72 with 
SVT and 
elevated 
troponin 
levels. 
Retrospective 
cohort. 
Raised troponin 
I leading to 
coronary 
angiography: 
All patients had normal 
coronary vessels on 
angiography. The 72 yo 
patient was also found to 
have evidence of 
hemodynamic 
compromise. 
Limited patient 
group with no 
comparison 
group of 
patients with 
SVT and CAD. 
Database entry 
was   
retrospective 
and subject to 
bias. 
Zellweger, 
M, et al.  
2003  
Switzerland 
4 adult 
patients ages 
44-57 with 
SVT and 
elevated 
troponins. 
Case series. Raised troponin 
I leading to 
subsequent 
testing for CAD 
All patients were 
determined to not have 
CAD as ruled out by 
echocardiography with 
gated myocardial 
perfusion (1 patient), 
stress echocardiography (2 
patients), and coronary 
angiogram (2 patients). 
Limited case 
series. 
Bakshi, 
T.K., et al  
2002  
New 
Zealand 
3 patients ages 
37-49 with 
SVT and 
elevated 
troponin 
levels. 
Prospective 
cohort. 
Consecutive 
patients with 
elevated 
troponins who 
underwent 
angiography for 
suspected 
coronary 
disease. 
2 patients had high 
likelihood of ACS 
according to 
electrocardiographic 
changes and 1 patient had 
low likelihood on ECG. 
All patients were found to 
have normal coronary 
arteries on angiography. 
Limited case 
series. 
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Author, 
date and 
country 
Patient group 
Study type 
(level of 
evidence) 
Outcomes Key results 
Study 
Weaknesses 
Miranda, 
RC, et al  
2006  
Brazil 
49 year-old 
female with 
SVT 
Case study. Elevated 
troponin I level. 
Patient was found to have 
normal coronary arteries 
on angiogram. 
A case study. 
Patanè, S, et 
al  
2009 
Italy 
49 year-old 
female with 
SVT 
Case study Elevated 
troponin level 
without clinical 
or ECG 
presentation of 
ACS. 
On echocardiography 
mitral regurge and mild 
interventricular septal 
hypertrophy were present. 
ECG did not reveal any 
significant changes.Patient 
recovered over several 
days with a return to 
baseline troponin I levels. 
A case study. 
Yeo, KK, et 
al.  
2006 
United 
States 
3 patients ages 
22-58 with 
SVT and 
elevated 
troponin 
levels. 
Case series. Elevated 
troponin I level. 
All patients were found to 
have normal coronary 
arteries on coronary 
angiography. 
Limited case 
series. 
Kanjwal et 
al, 
2008, 
USA 
7 patients ages 
18-67 with 
tachycardias 
(5 with SVTs) 
and elevated 
troponin 
levels. 
Case series All patients 
presented with 
chest comfort 
and elevated 
troponin levels 
and 
subsequently 
underwent 
coronary 
angiography. 
All patients underwent 
coronary angiography and 
were found to have 
normal epicardial vessels. 
There was no evidence of 
hemodynamic instability 
in any of the patients. 
Limited case 
series 
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PATHOPHYSIOLOGY  OF SUPRAVENTRICULAR 
TACCHYARRHYTHMIA 
    Supraventricular tachyarrhythmia is defined as  narrow complex 
arrhythmia (QRS <120 msec) with heart rate of 180- 240 beats / min 
usually arises either from the atria or within AV node or accessory 
pathways connecting  atria with ventricle. There are 2 types 
1. AVNRT 
2. AVRT 
Atrioventricular Nodal Reentrant tachycardia  
Normally there are some   differences in the electrical properties of 
the various tissue types in  the  AV node  which are  responsible for AV 
nodal reentrant tachycardia.  There are 2 types of pathways in AV node 
one is a slow one and other is a fast one
55
. In typical AVNRT the 
conduction occurs via slow pathway to depolarize the ventricle .The 
retrograde conduction occurs via fast pathway to reactivates the atria to 
form closed circuit. In atypical AVNRT the conduction first occurs via 
the fast pathway and retrograde conduction via the slow pathway
56
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Preexcitation Syndrome tachycardia or Atrioventricular 
reciprocating tachycardia  
          In most patients who have reciprocating tachycardias they have 
accessory pathways. The accessory pathways   conducts more rapidly 
than the normal AV node. After the ventricles have been excited, the 
impulse is able to enter the accessory pathway retrogradely and return to 
the atrium. A  closed circuit  loop of this type establishes the  tachycardia. 
In wolf  Parkinson syndrome there are 5 types of pathways
56
 
ORTHODROMIC       
In this group the antegrade conduction occurs via normal AV 
NODE retrograde conduction via accessory pathway giving rise to 
narrow complex long RP tachycardia 
ANTIDROMIC          
Sometimes the activation travels via the accessory pathway while 
the retrograde conduction is via the normal AV node  producing wide 
QRS tachycardia 
26 
 
 
 
 
 
These  accessory pathways  detected by electrophysiologic studies 
 
 
FIG 3 : RE-ENTRANT PATHWAYS IN BOTH AVRT AND      
AVNRT 
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FIG 4 : ECG SHOWING AVRT 
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FIG 5  : ECG SHOWING AVNRT 
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ECG FINDING IN 5 TYPES OF PATHWAY IN WPW 
SYNDROME 
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SIGNIFICANCE OF  CARDIAC  TROPONINS   IN 
ARRHYTHMIAS 
The repeated incidence of tacchyarrhythmias in these patients leads 
to  leads to  variable amount of myocardial injury leading to release of 
myofibrillar enzymes. Whatever the proposed mechanism for the enzyme 
elevation, the presence of significant troponins in the blood causes worse 
prognosis which indicates significant amount of myocardial damage had 
occurred already.  
Repeated episodes of tachyarrhythmias 
 
 
 
abnormal and incoherent myocardial  contraction 
 
 
 
 
shear stress on the myocardium and endocardium 
 
 
 
 
ischaemia of endocardium, with release of myocardial cytosolic pool 
 
 
 
 
leading on to reduced myocardial  contractility 
 
 
 
 
impending ventricular dysfunction 
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CAN THIS BE USED AS A PROGNOSTIC INDICATOR 
As there is minimal myocardial injury in the svt compared to ACS  
the utility of  using it as prognostic marker needs consideration  and 
further studies are needed to  evaluate this in detail 
AS  AN INDICATOR FOR  IMPENDING CARDIAC FAILURE IN 
ARRHYTHMIA  PATIENTS 
There is only minimal and ill sustained elevation of this cardiac 
enzymes in arrhythmia hence it’s utility as a marker for impending failure 
has to be considered. Moreover  chronic heart failure patients have 
elevated cardiac enzymes  and they are predisposed to variety of 
arrhythmias. Hence  further prospective studies are needed in future to 
assess impending failure in arrhythmic patients 
FALSE POSITVE TROPONIN IN THE HEALTHY  
VOLUNTEERS 
One percent of healthy volunteers who showed minor elevation of 
cTnT were considered as  false positive after eliminating the possibility 
of ACS by coronary angiography
57
. In general practice the significance of 
elevated troponins were interpreted based on clinical findings to avoid 
unnecessary procedure in these healthy patients. 
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Causes of false‐positively  elevated troponins58 
* Analyser or analyte malfunction 
* The presence of microparticles. 
* The presence of fibrin clots 
* Rhabdomyolysis 
* Heterophilic antibodies as seen in Paul bunell ‘s  test 
* Rheumatoid factor 
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AIM OF THE STUDY 
To study the clinical profile of non CAD supraventricular 
tachyarrhythmias 
To investigate the relationship of serum creatinine kinase(MB) and 
trponin I    in   this   patients. 
To identify whether any association exists between serum cardiac 
enzymes and the following parameters. 
Age 
Sex 
Blood pressure 
Alcohol 
Diabetes mellitus 
Smoking 
Obesity 
Hemoglobin 
Type of SVT 
Presence of LVH/diastolic dysfunction   in ECHO 
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BACKGROUND 
SELECTION OF SUBJECTS: 
Patients who admitted cardiac CCU department in Kilpauk 
Medical College Hospital with palpitation diagnosed as SVT by ECG 
after excluding exclusion criteria. 
INCLUSION CRITERIA: 
Supraventricular tachycardia diagnosed by ECG with heart rate 180 
to 240/min with regular narrow complex tachycardia either as AVRT or 
AVNRT 
EXCLUSION CRITERIA 
Acoholic Liver Diseases 
Cerebro vascular accident 
Patients with chronic heart failure 
Valvular heart disease 
Chronic kidney disease 
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Malignancy 
CAD with failure 
Infiltrative disorder 
Acute pulmonary embolism 
Chronic or current infections 
Use of anti-cancer drugs in the past 30days 
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MATERIALS AND METHODS 
Setting : Kilpauk Medical College 
Study design:Descriptive analytical study 
Period of study: 2010 May -2012 December 
Sample size:  75  subjects 
This study is to analyse the prevalence of supraventricular 
tachyarrhythmia due to non CAD causes and to analyse the various risk 
factors in them and to find the level of CK(MB) and troponin I in these 
patients . To study about any correlation  exists between the various risk 
factors and the cardiac enzymes level. 
Cases  are investigated by following measures. 
History –duration of CAD, symptoms, family history of CAD, 
smoking, alcohol intake, past history regarding the number of episode  of 
SVT were asked. 
General examination 
Weight 
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Systemic examination 
Blood pressure by sphygmomanometer 
12 lead Electrocardiogram in rhythm strip 
Complete blood count 
Renal function test 
ECHO  
- In transthoracic ECHO LV dysfunction, LV hypertrophy 
ejection fraction, valve sclerosis, calcification, the presence 
of diastolic dysfunction  are noted. 
ENZYME ANALYSIS 
Blood samples were taken immediately after admission and sent 
for assays. The cardiac troponins were measured using third generation 
immunoassays. Cardiac troponins are detected in the serum by the use of 
monoclonal antibodies to epitopes of cTnI and cTnT.  
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IMMUNE ASSAYS 
The continuous improvement of assay performance has reduced 
rates of false positive results over the years by eliminating heparin 
interference, or cross‐reactivity with skeletal muscle. Sometimes first and 
second generation troponin assays often shows positive results in patients 
with severe skeletal muscle injury because of an unspecific binding of 
skeletal muscle troponin T to the test tube59. Using a third generation 
cTnT assay,  we found no cross‐reactivity between cTnT and CK, neither 
in exercise‐induced skeletal muscle trauma nor after rhabdomyolysis.60 
NORMAL TROPONIN LEVELS LESS THAN 0.04 ng/ml 
NORMAL CK(MB) LEVELS LESS THAN  5.5 ng/ml 
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DATA  ANALYSIS 
AMONG THE    75  PATIENTS   I    HAVE STUDIED     52  
OF THEM   HAVE 
ELEVATED TROPONIN VALUES  AND   17 OF  THEM   
HAVE 
ELEVATED   CK(MB)  VALUES  DURING THEIR 
ADMISSION 
 
FIG :  6 
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FIG : 7 
 
FIG - 8 
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FIG : 9 
 
FIG : 10 
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Descriptive Statistics 
Among the data collected the mean and standard deviation of 
various variables have been calculated 
TABLE - 2 
 Mean Std. Deviation N 
AGE 57.07 15.302 75 
WEIGHT 69.67 14.063 75 
HB 10.636000 2.1198955 75 
CK-MB 4.186400 2.5871453 75 
Tn-i .607600 .4996021 75 
sys BP 128.48 25.923 75 
DIA BP 81.76 11.745 75 
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FIG : 11 
 
FIG : 12 
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F  
AGE 
WEIG
HT HB CK-MB Tn-i sys BP DIA BP 
AGE Pearson 
Correlation 
1 .042 -.276* .283* .142 .195 .120 
Sig. (2-tailed)  .717 .017 .014 .226 .093 .307 
N 75 75 75 75 75 75 75 
WEIGHT Pearson 
Correlation 
.042 1 .135 -.111 .035 .254* .100 
Sig. (2-tailed) .717  .248 .341 .767 .028 .395 
28N 75 75 75 75 75 75 75 
HB Pearson 
Correlation 
-.276* .135 1 -.024 .097 .020 .192 
Sig. (2-tailed) .017 .248  .836 .406 .864 .100 
N 75 75 75 75 75 75 75 
CK-MB Pearson 
Correlation 
.283* -.111 -.024 1 .340** .082 .202 
Sig. (2-tailed) .014 .341 .836  .003 .487 .082 
N 75 75 75 75 75 75 75 
Tn-i Pearson 
Correlation 
.142 .035 .097 .340** 1 .265* .295* 
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Sig. (2-tailed) .226 .767 .406 .003  .022 .010 
N 75 75 75 75 75 75 75 
sys BP Pearson 
Correlation 
.195 .254* .020 .082 .265* 1 .612** 
Sig. (2-tailed) .093 .028 .864 .487 .022  .000 
N 75 75 75 75 75 75 75 
DIA BP Pearson 
Correlation 
.120 .100 .192 .202 .295* .612** 1 
Sig. (2-tailed) .307 .395 .100 .082 .010 .000  
N 75 75 75 75 75 75 75 
*. Correlation is significant at the 0.05 level . TABLE 3 
 
FIG : 13 
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IN ABOVE TABLE THE CORRELATION BETWEEN  VARIOUS 
VARIABLES   HAVE  BEEN  SOUGHT OUT USING  PEARSON 
CORRELATION TECHNIQUE 
CK-MB AGE 
WEIGHT SYSTOLIC BP 
HEMOGLOBIN AGE 
CK – MB TROPONIN 
SYSTOLIC BP TROPONIN  
DIASTOLIC BP CK – MB 
DIASTOLIC BP TROP - I 
 
 Correlation was found between the above said parameters. 
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FIG : 14 
CK-MB IN VARIOUS AGE GROUPS 
TABLE 4 
MORE HIGH AT THE UPPER LIMIT OF NORMAL IN AGE> 60 
 
 
95% Confidence Interval for 
Mean  
30 N Mean Std. Deviation Std. Error Lower Bound Upper Bound Minimum Maximum 
AGE<40 10 3.693000 2.4649816 .7794956 1.929658 5.456342 .0600 9.0000 
AGE 40-
60 
31 3.539677 2.1680459 .3893925 2.744432 4.334923 .0800 9.0000 
AGE>60 34 4.921176 2.8383262 .4867689 3.930838 5.911515 .4600 10.8000 
Total 75 4.186400 2.5871453 .2987378 3.591152 4.781648 .0600 10.8000 
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ANOVA 
TABLE 5 
CK-MB                                       
 Sum of 
Squares Df 
Mean 
Square F Sig. 
Between Groups 33.757 2 16.878 2.633 .079 
Within Groups 461.549 72 6.410   
Total 495.306 74    
 
THIS TABLE SHOWS A MARGINAL SIGNIFICANCE OF 
TROPONIN ELEVATION IN AGE> 60 YRS 
TABLE 6 
TROPONIN I                                  
  95% Confidence Interval for Mean 
31 
N Mean 
Std. 
Deviation 
Std. 
Error 
Lower 
Bound 
Upper 
Bound Minimum Maximum 
AGE<40 10 .494000 .3242838 .1025475 .262021 .725979 .0400 .9200 
AGE 
40-60 
31 .536774 .4165284 .0748107 .383990 .689558 .0200 1.4600 
AGE>60 34 .705588 .5956468 .1021526 .497757 .913419 .0200 2.8000 
Total 75 .607600 .4996021 .0576891 .492652 .722548 .0200 2.8000 
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FIG  : 15 
ANOVA 
TABLE 7 
TROPONIN I                                 
 Sum of 
Squares Df 
Mean 
Square F Sig. 
Between Groups .611 2 .306 1.232 .298 
Within Groups 17.860 72 .248   
Total 18.471 74    
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THERE IS NO SIGNIFICANT ELEVATION IN THE VARIOUS 
AGE GROUPS 
MULTIPLE COMPARISONS 
TABLE 8 
Tn-I 
32 
(J) 
AGEGR
OUP 
 95% Confidence Interval 
Mean Difference (I-
J) Std. Error Sig. Lower Bound Upper Bound 
1 40-60YR -.0427742 .1811257 .814 -.403842 .318293 
>60 YRS -.2115882 .1791661 .242 -.568749 .145573 
2 20-40 .0427742 .1811257 .814 -.318293 .403842 
>60 YRS -.1688140 .1236817 .177 -.415369 .077741 
3 20-40YR .2115882 .1791661 .242 -.145573 .568749 
40-60 YR .1688140 .1236817 .177 -.077741 .415369 
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TABLE - 9 
Descriptives   
  
 
95% Confidence Interval for 
Mean 
  
N Mean 
Std. 
Deviation Std. Error Lower Bound Upper Bound 
CK-MB >60 66 4.385303 2.6352511 .3243770 3.737477 5.033129 
40-60 7 3.208571 1.4679172 .5548206 1.850974 4.566168 
20-40 1 .060000 . . . . 
<20 1 2.030000 . . . . 
Total 75 4.186400 2.5871453 .2987378 3.591152 4.781648 
Tn-i >60 66 .626515 .5218915 .0642404 .498218 .754812 
40-60 7 .528571 .2451821 .0926701 .301816 .755327 
20-40 1 .040000 . . . . 
<20 1 .480000 . . . . 
Total 75 .607600 .4996021 .0576891 .492652 .722548 
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TABLE - 10 
 
Descriptives 
   
  Minimum Maximum 
CK-MB >60 .0800 10.8000 
40-60 .4600 4.8000 
20-40 .0600 .0600 
<20 2.0300 2.0300 
Total .0600 10.8000 
Tn-i >60 .0200 2.8000 
40-60 .0800 .8000 
20-40 .0400 .0400 
<20 .4800 .4800 
Total .0200 2.8000 
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ANOVA                                  
TABLE 11 
  Sum of Squares Df Mean Square F Sig. 
CK-MB Between Groups 30.981 3 10.327 1.579 .202 
Within Groups 464.324 71 6.540   
Total 495.306 74    
Tn-i Between Groups .406 3 .135 .532 .662 
Within Groups 18.065 71 .254   
Total 18.471 74    
 
FROM THE ABOVE TABLE, THE INFERENCE IS AGE HAVE 
NO IMPACT ON THE ELEVATED ENZYMES IN  SVT  PATIENTS 
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Correlations 
TABLE 12 
CORRELATION OF NO OF EPISODE WITH ENZYME 
ELEVATION 
  EPISODE CK-MB Tn-i 
EPISODE Pearson Correlation 1 -.228* -.113 
Sig. (2-tailed)  .049 .333 
N 75 75 75 
CK-MB Pearson Correlation -.228* 1 .340** 
Sig. (2-tailed) .049  .003 
N 75 75 75 
Tn-i Pearson Correlation -.113 .340** 1 
Sig. (2-tailed) .333 .003  
N 75 75 75 
 
FROM THE ABOVE TABLE THERE IS  SIGNIFICANT 
PROBABILITY BETWEEN NO OF EPISODES OF SVT WITH 
CK(MB) . NOSIGNIFICANT ASSOCIATION  BETWEEN 
TROPONIN AND THE NO OF EPISODE 
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CORRELATION OF NO OF EPISODE WITH ENZYME 
ELEVATION 
  EPISODE CK-MB Tn-i 
EPISODE Pearson Correlation 1 -.228* -.113 
Sig. (2-tailed)  .049 .333 
N 75 75 75 
CK-MB Pearson Correlation -.228* 1 .340** 
Sig. (2-tailed) .049  .003 
N 75 75 75 
Tn-i Pearson Correlation -.113 .340** 1 
Sig. (2-tailed) .333 .003  
N 75 75 75 
 
FROM THE ABOVE TABLE THERE IS  SIGNIFICANT 
PROBABILITY BETWEEN NO OF EPISODES OF SVT WITH 
CK(MB) . NOSIGNIFICANT ASSOCIATION  BETWEEN 
TROPONIN AND THE NO OF EPISODE 
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SEX AND AGE GROUP 
TABLE 13 
 
   AGEGROUP  
   <40 40-60 >60 Total 
SEX 1 Count 5 24 19 48 
% within AGEGROUP 50.0% 77.4% 55.9% 64.0% 
% of Total 6.7% 32.0% 25.3% 64.0% 
2 Count 5 7 15 27 
% within AGEGROUP 50.0% 22.6% 44.1% 36.0% 
% of Total 6.7% 9.3% 20.0% 36.0% 
 Total Count 10 31 34 75 
% within AGEGROUP 100.0% 100.0% 100.0% 100.0% 
% of Total 13.3% 41.3% 45.3% 100.0% 
 
Chi-Square Tests                TABLE 14 
 
Value Df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 4.246a 2 .120 
Likelihood Ratio 4.370 2 .113 
Linear-by-Linear 
Association 
.218 1 .641 
N of Valid Cases 75   
 
FROM  THE CORRELATION, THERE IS NO SIGNIFICANT  
PROBABILITY WITH AGE OF INCIDENCE  OF SVT WITH SEX. 
BOTH ARE EQUALLY AFFECTED 
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FIG  : 16 
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EPISODE * AGEGROUP                             
 
TABLE 15 
 
   AGEGROUP  
   <40 40-60 >60 Total 
EPISODE 1 Count 8 28 30 66 
% within AGEGROUP 80.0% 90.3% 88.2% 88.0% 
% of Total 10.7% 37.3% 40.0% 88.0% 
2 Count 0 3 4 7 
% within AGEGROUP .0% 9.7% 11.8% 9.3% 
% of Total .0% 4.0% 5.3% 9.3% 
3 Count 1 0 0 1 
% within AGEGROUP 10.0% .0% .0% 1.3% 
% of Total 1.3% .0% .0% 1.3% 
4 Count 1 0 0 1 
% within AGEGROUP 10.0% .0% .0% 1.3% 
% of Total 1.3% .0% .0% 1.3% 
 Total Count 10 31 34 75 
% within AGEGROUP 100.0% 100.0% 100.0% 100.0% 
% of Total 13.3% 41.3% 45.3% 100.0% 
 
 
Chi-Square Tests                       
TABLE 16 
 
Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 14.245a 6 .027 
Likelihood Ratio 10.223 6 .116 
Linear-by-Linear 
Association 
2.640 1 .104 
N of Valid Cases 75   
 
 
 FROM ABOVE TABLE COMPARING VARIOUS AGE 
GROUP WITH NO OF EPISODES, IT SEEMS THAT THERE IS 
SIGNIFICANT PROBABILITY 
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FIG : 17 
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SMOKING * AGEGROUP    
TABLE 17 
 
 
   AGEGROUP  
   <40 40-60 >60 Total 
SMOKING NON 
SMOKER 
Count 6 14 24 44 
% within AGEGROUP 60.0% 45.2% 70.6% 58.7% 
% of Total 8.0% 18.7% 32.0% 58.7% 
SMOKER Count 4 17 10 31 
% within AGEGROUP 40.0% 54.8% 29.4% 41.3% 
% of Total 5.3% 22.7% 13.3% 41.3% 
 Total Count 10 31 34 75 
% within AGEGROUP 100.0% 100.0% 100.0% 100.0% 
% of Total 13.3% 41.3% 45.3% 100.0% 
 
 
Chi-Square Tests               
 
TABLE 18 
 
 Value Df Asymp. Sig. (2-sided) 
Pearson Chi-Square 4.332a 2 .115 
Likelihood Ratio 4.369 2 .113 
Linear-by-Linear 
Association 
1.721 1 .190 
N of Valid Cases 75   
 
THERE IS NOSIGNIFICANT DIFFERENCE WITH 
OCCURRENCE OF SVT AND SMOKING 
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FIG : 18 
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ALCOHOL * AGEGROUP 
 
TABLE 19 
   AGEGROUP  
   <40 40-60 >60 Total 
ALCOHOL NONAL
COHOL
IC 
Count 7 17 27 51 
% within AGEGROUP 70.0% 54.8% 79.4% 68.0% 
% of Total 9.3% 22.7% 36.0% 68.0% 
ALCOH
OLIC 
Count 3 14 7 24 
% within AGEGROUP 30.0% 45.2% 20.6% 32.0% 
% of Total 4.0% 18.7% 9.3% 32.0% 
 Total Count 10 31 34 75 
% within AGEGROUP 100.0% 100.0% 100.0% 100.0% 
% of Total 13.3% 41.3% 45.3% 100.0% 
 
 
Chi-Square Tests                                 
TABLE 20 
 
 Value Df Asymp. Sig. (2-sided) 
Pearson Chi-Square 4.521a 2 .104 
Likelihood Ratio 4.554 2 .103 
Linear-by-Linear 
Association 
1.691 1 .194 
N of Valid Cases 75   
 
THE INFERENCE FROM ABOVE TABLE IS THERE IS NO 
SIGNIFICANT DIFFERENCE BETWEEN BOTH ALCOHOLIC AND 
NON ALCOHOLIC  WITH  OCCURRENCE OF SVT 
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FIG : 19 
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DIABETES * AGEGROUP 
TABLE 21 
 
   AGEGROUP  
   <40 40-60 >60 Total 
DIABETES NON 
DIABETIC 
Count 9 16 17 42 
% within AGEGROUP 90.0% 51.6% 50.0% 56.0% 
% of Total 12.0% 21.3% 22.7% 56.0% 
DIABETIC Count 1 15 17 33 
% within AGEGROUP 10.0% 48.4% 50.0% 44.0% 
% of Total 1.3% 20.0% 22.7% 44.0% 
 Total Count 10 31 34 75 
% within AGEGROUP 100.0% 100.0% 100.0% 100.0% 
% of Total 13.3% 41.3% 45.3% 100.0% 
 
 
Chi-Square Tests                                  
 
TABLE 22 
 
 
Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 5.430a 2 .066 
Likelihood Ratio 6.311 2 .043 
Linear-by-Linear 
Association 
3.263 1 .071 
N of Valid Cases 75   
 
THERE IS SIGNIFICANT DIFFERENCE WITH  
OCCURRENCE OF SVT IN DIABETIC AND NON DIABETIC 
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                                                FIG - 20 
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HYPERTENSION * AGEGROUP 
 
TABLE 23 
 
   AGEGROUP  
   <40 40-60 >60 Total 
HYPERTENSION NO Count 8 17 15 40 
% within AGEGROUP 80.0% 54.8% 44.1% 53.3% 
% of Total 10.7% 22.7% 20.0% 53.3% 
YES Count 2 14 19 35 
% within AGEGROUP 20.0% 45.2% 55.9% 46.7% 
% of Total 2.7% 18.7% 25.3% 46.7% 
 Total Count 10 31 34 75 
% within AGEGROUP 100.0% 100.0% 100.0
% 
100.0% 
% of Total 13.3% 41.3% 45.3% 100.0% 
 
 
Chi-Square Tests                       
TABLE 24 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 4.046a 2 .132 
Likelihood Ratio 4.284 2 .117 
Linear-by-Linear 
Association 
3.672 1 .055 
N of Valid Cases 75   
 
FROM THE ABOVE TABLE THERE IS NO DIFFERENCE IN 
OCCURRENCE OF SVT IN HYPERTENSIVES AND NON 
HYPERTENSIVES 
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                                                 FIG 21 
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ECG * AGEGROUP                    
 
TABLE 25 
 
 
   AGEGROUP  
   <40 40-60 >60 Total 
ECG AVNRT Count 8 30 32 70 
% within 
AGEGROUP 
80.0% 96.8% 94.1% 93.3% 
% of Total 10.7% 40.0% 42.7% 93.3% 
AVRT Count 2 1 2 5 
% within 
AGEGROUP 
20.0% 3.2% 5.9% 6.7% 
% of Total 2.7% 1.3% 2.7% 6.7% 
 Total Count 10 31 34 75 
% within 
AGEGROUP 
100.0% 100.0% 100.0% 100.0% 
% of Total 13.3% 41.3% 45.3% 100.0% 
 
Chi-Square Tests                           
TABLE 26 
 Value Df Asymp. Sig. (2-sided) 
Pearson Chi-Square 3.481a 2 .175 
Likelihood Ratio 2.683 2 .261 
N of Valid Cases 75   
 
THERE IS A  PROPORTIONATE INCIDENCE IN 
OCCURRENCE OF SVT IN 3 DIFFERENT AGE GROUPS but no 
significant correlation between age and type of  SVT 
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ECHO * AGEGROUP                                                     
TABLE 27 
 
   AGEGROUP  
   <40 40-60 >60 Total 
ECHO N STUDY Count 6 23 19 48 
% within AGEGROUP 60.0% 74.2% 55.9% 64.0% 
% of Total 8.0% 30.7% 25.3% 64.0% 
AV 
SCLEROSIS 
Count 0 1 1 2 
% within AGEGROUP .0% 3.2% 2.9% 2.7% 
% of Total .0% 1.3% 1.3% 2.7% 
ATHELETE’
S HEART 
Count 1 0 0 1 
% within AGEGROUP 10.0% .0% .0% 1.3% 
% of Total 1.3% .0% .0% 1.3% 
GRADE 
1,2DD 
Count 0 1 1 2 
% within AGEGROUP .0% 3.2% 2.9% 2.7% 
% of Total .0% 1.3% 1.3% 2.7% 
GRADE3, 
DD 
Count 0 5 10 15 
% within AGEGROUP .0% 16.1% 29.4% 20.0% 
% of Total .0% 6.7% 13.3% 20.0% 
GRADE 
4DD 
Count 0 0 1 1 
% within AGEGROUP .0% .0% 2.9% 1.3% 
% of Total .0% .0% 1.3% 1.3% 
AORTIC 
STENOSIS 
Count 0 0 1 1 
% within AGEGROUP .0% .0% 2.9% 1.3% 
% of Total .0% .0% 1.3% 1.3% 
MITRL 
VALVE 
PROLAPSE 
Count 1 1 0 2 
% within AGEGROUP 10.0% 3.2% .0% 2.7% 
% of Total 1.3% 1.3% .0% 2.7% 
WPW Count 2 0 1 3 
% within AGEGROUP 20.0% .0% 2.9% 4.0% 
% of Total 2.7% .0% 1.3% 4.0% 
 Total Count 10 31 34 75 
% within AGEGROUP 100.0% 100.0% 100.0% 100.0% 
% of Total 13.3% 41.3% 45.3% 100.0% 
72 
 
 
 
 
 
CHISQUARETESTS        
 
TABLE  28 
 
 
Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 24.848a 16 .073 
Likelihood Ratio 23.627 16 .098 
Linear-by-Linear 
Association 
.000 1 .996 
N of Valid Cases 75   
 
There is a significant correlation between occurrence of SVT with 
various echo findings. 
 
                                         FIG : 24 
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FIG 25 
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LVH * AGEGROUP                           
TABLE 29 
 
   AGEGROUP  
   <40 40-60 >60 Total 
LVH NO Count 9 23 16 48 
% within AGEGROUP 90.0% 74.2% 47.1% 64.0% 
% of Total 12.0% 30.7% 21.3% 64.0% 
YES Count 1 8 18 27 
% within AGEGROUP 10.0% 25.8% 52.9% 36.0% 
% of Total 1.3% 10.7% 24.0% 36.0% 
 Total Count 10 31 34 75 
% within AGEGROUP 100.0% 100.0% 100.0% 100.0% 
% of Total 13.3% 41.3% 45.3% 100.0% 
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FIG : 26 
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Chi-Square Tests                               
TABLE 30 
 
Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 8.567a 2 .014 
Likelihood Ratio 9.091 2 .011 
Linear-by-Linear 
Association 
8.241 1 .004 
N of Valid Cases 75   
 
THE INFERENCE FROM ABOVE  TABLE  THERE IS 
SIGNIFICANCE IN OCURRENCE OF SVT WITH PRESENCE OF 
LVH 
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FIG : 27 
HEMOGLOBIN  
 
 
                                             
FIG : 28 
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INFERENCES FROM THE STUDY 
By pearson correlation analysis 
1. There is no correlation between various age group, occurrence 
of SVT. 
2. There is significant  no correlation between occurrence of SVT 
with sex. 
3. There is no significant correlation between occurrence of SVT   
with alcohol and smoking. 
4. There is a significant correlation of SVT occurrence and 
diabetes but there is  no correlation with hypertension there is 
significant correlation between weight and troponin  I which is 
directly proportional. 
5. There is a direct correlation between the no of episodes with age 
more than 60 affected. 
6. There is direct correlation of left ventricular hypertrophy in 
ECHO with incidence of SVT. 
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7. There is also a direct correlation between  weight  and CK(MB) 
in this study. 
8. There is also a direct correlation between weight and CK(MB) 
in this study. 
9. There is  correlation between hemoglobin and CK(MB) levels. 
10. There is correlation between age and CK (MB) levels. 
11. Systolic BP is  in correlation with CK(MB) and troponin I. 
BOTH are directly proportional 
12. There is a significant correlation with diastolic BP and troponin 
I levels. 
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DISCUSSION AND INTERPRETATION 
In  this observational study I have studied I first calculated the 
prevalence of SVT in  non CAD and non valvular heart disease patients. 
The prevalence is about 80 cases within study period 
       All the patients underwent complete investigation and they were 
analysed whether there is any significant elevation of both creatinine 
kinase and troponin I levels in this patient and whether there is any 
association between various risk factors and the level of enzymes 
* The mean age group is 57 years 
* The mean elevation of CK(MB) is 4.18ng/ml 
* The mean elevation of troponin I is 0.60 ng/ml 
* The  cardiac enzyme elevation is directly proportional to 
both systolic and diastolisc BP 
* The creatinine kinase elevation increases with increase in 
age 
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* The level of hemoglobin is indirectly proportional to 
creatinine kinase level.  With anemia there will be increasing 
level of (CK-MB) levels. This anemia is  more common in 
old age and common in females compared to males 
* Those patients who are hypertensive have higher incidence 
of  SVT compared to non hypertensive patients 
*  There is a significant difference in occurrence of SVT with 
Diabetics and Non diabetics 
*  There is no significant difference in both incidence of SVT 
and enzyme variation in smokers and non smokers 
*  There is no significant difference in both incidence of SVT 
and enzyme variation in alcoholics and non alcoholics,but 
alcoholics have recurrent episode of SVT 
*  The SVT  is more common in obese patients with mean 
weight of above 70 kg 
*  With increasing incidence of obesity, there is increased 
prevalence of both hypertension and obesity 
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* The presence of left ventricular hypertrophy and diastolic 
dysfunction in ECHO which represents the severe form of 
hypertension is more common in older age compared to 
middle age and they have direct correlation with occurrence 
of SVT 
*  There is no significant correlation between the elevated 
troponin I with presence of left ventricular hypertrophy in 
adults. 
*  The most commonest form of SVT is AVNRT and the 
patients with WPW get recurrent episodes of AVRT 
*  Even mitral valve prolapse  patients  can have sudden 
incidence of SVT 
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CONCLUSION 
Troponin levels are essential for the diagnosis of myocardial 
infarction. But it was not pathognomic for ACS
61
. It was found recently 
that it was elevated in some severe acute diseases like acute pulmonary 
thrombo embolism, stroke,  pericarditis,  ESRD,  most importantly 
sepsis
62
. As a result the elevated troponin levels should be interpreted in 
text of clinical finding. Sometimes these troponin elevation leads to 
misdiagnosis and  can cause unnecessary tests and treatments to be 
ordered, leading to delay in proper diagnosis and treatment
63
. 
            In a patient with SVT, the use of troponin testing would best be 
performed selectively based on presenting symptoms and risk factors for 
acute coronary syndrome
64
. In the absence of clinical  coronary artery 
disease, troponin levels may point  to minor myocardial injury
65
, as 
shown by the cases of  supraventricular tachyarrythmia. Apart from this, 
the elevated troponins in these group of patients indicates worser 
prognosis. Follow up prospective studies are needed  to prove this new 
concepts.  
 
84 
 
 
 
 
BIBLIOGRAPHY 
1. Alpert J S, Thygesen K, Antman E. et al Myocardial infarction 
redefined—a consensus document of the Joint European Society 
of Cardiology/American College of Cardiology committee for the 
redefinition of myocardial infarction. J Am Coll 
Cardiol 2000. 36959–969.969This paper is of great importance 
because it completely changed our definition of MI. Since the year 
2000, MI is defined by an elevation of cardiac troponin I or T in the 
clinical setting of ischaemia. [PubMed] 
 
2. Parmacek M S, Solaro R J. Biology of the troponin complex in 
cardiac myocytes. Prog Cardiovasc Dis2004. 47159–
176.176. [PubMed] 
 
3. Ottani F, Galvani M, Nicolini F A. et al Elevated cardiac troponin 
levels predict the risk of adverse outcome in patients with acute 
coronary syndromes. Am Heart J 2000. 140917–
927.927. [PubMed] 
 
4. Aviles R J, Askari A T, Lindahl B. et al Troponin T levels in patients 
with acute coronary syndromes, with or without renal 
dysfunction. N Engl J Med 2002. 3462047–2052.2052This large 
prospective study on 7033 patients with acute coronary syndrome 
and concomitant renal impairment clearly demonstrated that 
elevated cardiac troponin T predicts short term prognosis 
regardless of the creatinine clearance. [PubMed] 
 
85 
 
 
 
 
5. Ricciardi M J, Davidson C J, Gubernikoff G. et al Troponin I 
elevation and cardiac events after percutaneous coronary 
intervention. Am Heart J 2003. 145522–528.528In their 
prospective study on 286 patients the authors showed that 
elevated cardiac troponins following PCI are equally predictive for 
major adverse cardiac event, especially for early repeat 
vascularisation, as  CK-MB [PubMed] 
 
6. Lehrke S, Steen H, Sievers H H. et al Cardiac troponin T for prediction f short‐ and 
long‐term morbidity and mortality after elective open heart surgery. Clin 
Chem 2004. 501560–1567.1567.[PubMed] 
 
7. Dokainish H, Pillai M, Murphy S A. et al Prognostic implications of 
elevated troponin in patients with suspected acute coronary syndrome but no 
critical epicardial coronary disease: a TACTICS‐TIMI‐18 substudy. J Am Coll 
Cardiol 2005. 4519–24.24. [PubMed] 
 
8. Spies C, Haude V, Fitzner R. et al Serum cardiac troponin T as a 
prognostic marker in early sepsis.Chest 1998. 1131055–
1063.1063. [PubMed] 
 
9. Giannitsis E, Muller‐Bardorff M, Kurowski V. et al Independent 
prognostic value of cardiac troponin T in patients with confirmed 
pulmonary embolism. Circulation 2000. 102211–217.217In this study 
conducted by our group, elevated cTnT values in acute pulmonary 
embolism were identified as a prognostic risk factor of in‐hospital 
mortality. [PubMed] 
 
10. Muller‐Bardorff M, Weidtmann B, Giannitsis E. et al Release kinetics of 
cardiac troponin T in survivors of confirmed severe pulmonary 
embolism. Clin Chem 2002. 48673–675.675. [PubMed] 
 
86 
 
 
 
 
11. Katus H A, Remppis A, Neumann F J. et al Diagnostic efficiency of 
troponin T measurements in acute myocardial infarction. 
 Circulation 1991. 83902–912.912This study conducted in the early 
1990s is of major importance because it showed the outstanding role of 
cTnT for the diagnosis of AMI. [PubMed] 
 
12. Missov E, Mair J. A novel biochemical approach to congestive heart 
failure: cardiac troponin T. Am Heart J 1999. 13895–99.99In a study on 
80 patients with congestive heart failure, Missov and colleagues found 
that the cTnT level represents the severity of the disease and that cTnT 
could be a molecular marker for non‐invasive monitoring of congestive 
heart failure from a structural perspective. [PubMed] 
 
13. La Vecchia L, Mezzena G, Zanolla L. et al Cardiac troponin I as 
diagnostic and prognostic marker in severe heart failure. J Heart Lung 
Transplant 2000. 19644–652.652. [PubMed] 
 
14. Neumayr G, Gaenzer H, Pfister R. et al Plasma levels of cardiac 
troponin I after prolonged strenuous endurance exercise. Am J 
Cardiol 2001. 87369–71, A10.71, A10. [PubMed] 
 
15. Dengler T J, Zimmermann R, Braun K. et al Elevated serum 
concentrations of cardiac troponin T in acute allograft rejection after 
human heart transplantation. J Am Coll Cardiol 1998. 32405–
412.412.[PubMed] 
 
16. Apple F S, Murakami M M, Pearce L A. et al Predictive value of cardiac 
troponin I and T for subsequent death in end‐stage renal 
disease. Circulation 2002. 1062941–2945.2945. [PubMed] 
 
17. Wu A H, Feng Y J. Biochemical differences between cTnT and cTnI 
and their significance for diagnosis of acute coronary syndromes. Eur 
Heart J 1998. 19N25–N29.N29. [PubMed] 
 
87 
 
 
 
 
18. Haller C, Zehelein J, Remppis A. et al Cardiac troponin T in patients 
with end‐stage renal disease: absence of expression in truncal skeletal 
muscle. Clin Chem 1998. 44930–938.938. [PubMed] 
 
19. Dierkes J, Domrose U, Westphal S. et al Cardiac troponin T predicts 
mortality in patients with end‐stage renal disease. Circulation  
2000. 1021964–1969.1969. [PubMed] 
20. Lavoinne A, Hue G. Serum cardiac troponins I and T in early 
posttraumatic rhabdomyolysis. Clin Chem 1998. 44667–
668.668. [PubMed] 
 
21. Myocardial infarction redefined--a consensus document of The Joint 
European Society of Cardiology/American College of Cardiology 
Committee for the redefinition of myocardial infarction.[J Am Coll 
Cardiol. 2000] 
 
22. Elevated cardiac troponin levels predict the risk of adverse outcome in 
patients with acute coronary syndromes.[Am Heart J. 2000] 
 
23. Troponin T levels in patients with acute coronary syndromes, with or 
without renal dysfunction.[N Engl J Med. 2002] 
 
24. Troponin I elevation and cardiac events after percutaneous coronary 
intervention.[Am Heart J. 2003] 
 
25. Cardiac troponin T for prediction of short- and long-term morbidity and 
mortality after elective open heart surgery.[Clin Chem. 2004] 
 
26. Prognostic implications of elevated troponin in patients with suspected 
acute coronary syndrome but no critical epicardial coronary disease: a 
TACTICS-TIMI-18 substudy.[J Am Coll Cardiol. 2005] 
 
27. Serum cardiac troponin T as a prognostic marker in early sepsis.[Chest. 
1998] 
88 
 
 
 
 
 
28. Independent prognostic value of cardiac troponin T in patients with 
confirmed pulmonary embolism.[Circulation. 2000] 
 
29. Release kinetics of cardiac troponin T in survivors of confirmed severe 
pulmonary embolism.[Clin Chem. 2002] 
 
30. Diagnostic efficiency of troponin T measurements in acute myocardial 
infarction.[Circulation. 1991] 
 
31. Independent prognostic value of cardiac troponin T in patients with 
confirmed pulmonary embolism.[Circulation. 2000] 
 
32. A novel biochemical approach to congestive heart failure: cardiac 
troponin T.[Am Heart J. 1999] 
 
33. Cardiac troponin I as diagnostic and prognostic marker in severe heart 
failure.[J Heart Lung Transplant. 2000] 
 
34. Plasma levels of cardiac troponin I after prolonged strenuous endurance 
exercise.[Am J Cardiol. 2001] 
 
35. Elevated serum concentrations of cardiac troponin T in acute allograft 
rejection after human heart transplantation.[J Am Coll Cardiol. 1998] 
 
36. Troponin T levels in patients with acute coronary syndromes, with or 
without renal dysfunction.[N Engl J Med. 2002] 
 
37. Predictive value of cardiac troponin I and T for subsequent death in end-
stage renal disease.[Circulation. 2002] 
 
38.  Biochemical differences between cTnT and cTnI and their significance 
for diagnosis of acute coronary syndromes.[Eur Heart J. 1998] 
 
89 
 
 
 
 
39. Cardiac troponin T in patients with end-stage renal disease: absence of 
expression in truncal skeletal muscle.[Clin Chem. 1998] 
 
40. Predictive value of cardiac troponin I and T for subsequent death in end-
stage renal disease.[Circulation. 2002] 
 
41. Cardiac troponin T predicts mortality in patients with end-stage renal 
disease.[Circulation. 2000] 
42. Serum cardiac troponins I and T in early posttraumatic 
rhabdomyolysis.[Clin Chem. 1998 
 
43. Normal coronary arteries International Journal of Cardiology 2005; 521-
522 
 
44. Zellweger, M, et al. Elevated troponin levels in the abscence of coronary 
artery disease after Redfearn, et al. Supraventricular tachycardia 
promotes release of troponin I in patients with supraventricular 
tachycardia Swiss Medical Weekly 2003; 439-441 
 
45. Bakshi, T.K., et al. Causes of elevated troponin I in normal coronary 
angiogram Internal Medicine Journal 2002; 520-525 
 
46. Miranda, RC, et al. Elevated troponin levels after prolonged 
supraventricular tachycardia in patient with normal coronary 
angiography Cardiology 2006; 106 
 
47. Patanè, S, et al Abnormal troponin levels after supraventricular 
tachycardia Internal Journal of Cardiology 2009; 57-59 
 
48. Yeo, KK, et al Tachycardia-induced elevation in cardiac troponin in the 
abscence of coronary artery disease Hawaii Medical Journal 2006; 86-87 
 
90 
 
 
 
 
49. Kanjwal K, Imran N, Grubb B, et al. Troponin elevation in patients with 
various tachycardias and normal epicardial coronaries. Indian Pacing 
Electrophysiology Journal. 2008;8(3):172-4. 
 
50. Carlbert DJ, Tsuchitani S, Barlotta KS, et al. Serum troponin testing in 
patients with paroxysmal supraventricular tachycardia: outcome after 
ED care. Am J Emerg Med 2011;29:545-548. 
 
51. Bolton E. Disturbances of cardiac rhythm and conduction.  
In:  Tintinalli  JE, Kelen  GD,  Stapczynski  JS editor.  Emergency 
medicine: a comprehensive study guide. 6th ed. New York: 
ACEP; 2004;p. 185–187 
 
52. Hamm CW, Goldmann BU, Heeschen C, et al. Emergency room triage 
of 5patients with acute chest pain by means of rapid testing for cardiac 
troponin T or troponin I. N Engl J Med. 1997;337:1648–1653 
 
53. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific 
troponin I levels to predict the risk of mortality in patients with acute 
coronary syndromes. N Engl J Med. 1996;335:1342–1349 
 
54. Kontos MC, Shah R, Fritz LM, Anderson FP, Tatum JL, Ornato JP, 
et al. Implication of different cardiac troponin I levels for clinical 
outcomes and prognosis of acute chest pain patients. J Am Coll 
Cardiol. 2004;43:958–965 
 
55. Pham MX, Whooley MA, Evans GT, et al. Prognostic value of low-
level cardiac troponin-I elevations in patients without definite acute 
coronary syndromes. Am Heart J. 2004;148:776–782 
 
56. Higgins JP, Higgins JA. Elevation of cardiac troponin I indicates more 
than myocardial ischemia. Clin Invest Med. 2003;26:133–147 
 
91 
 
 
 
 
57. Ilva TJ, Eskola MJ, Nikus KC, et al. The etiology and prognostic 
significance of all-cause troponin I positivity in emergency department 
patients. J Emerg Med. 2010;38:1–5 
 
58. Yin WH, Chen JW, Feng AN, Lin SJ, Young S. Multimarker approach 
to risk stratification among patients with advanced chronic heart 
failure. Clin Cardiol. 2007;30:397–402 
 
59. Mueller C. Risk stratification in acute decompensated heart failure: the 
role of cardiac troponin. Nat Clin Pract Cardiovasc Med. 2008;5:680–
681 
58. Zellweger MJ, Schaer BA, Cron TA, Pfisterer ME, Osswald S. Elevated 
troponin levels in the absence of coronary artery disease after 
supraventricular tachycardia. Swiss Med Wkly. 2003;133:439–441 
 
59. Elikowski W, Baszko A, Wroblewski D, Slomczynski M, 
Malek M. Supraventricular tachycardia as a cause of elevated troponin I 
in a patient with normal coronary arteries. Pol Merkur 
Lekarski. 2005;18:696–699 
 
60. Redfearn DP, Ratib K, Marshall HJ, Griffith MJ. Supraventricular 
tachycardia promotes release of troponin I in patients with normal 
coronary arteries. Int J Cardiol. 2005;102:521–522 
 
61. Bakshi TK, Choo MK, Edwards CC, et al. Causes of elevated troponin I 
with a normal coronary angiogram. Intern Med J.2002;32:520–525 
 
62. Kanjwal K, Imran N, Grubb B, Kanjwal Y. Troponin elevation in 
patients with various tachycardias and normal epicardial 
coronaries. Indian Pacing Electrophysiol J. 2008;8:172–174 
 
63. Adams JE, Bodor GS, Davila-Roman VG, et al. Cardiac troponin I. A 
marker with high specificity for cardiac 
injury. Circulation.1993;88:101–106 
 
92 
 
 
 
 
64. Jeremias A, Gibson CM. Narrative review: alternative causes for 
elevated cardiac troponin levels when acute coronary syndromes are 
excluded. Ann Intern Med. 2005;142:786–791 
 
65. Qi WF, Kjekshus HF, Klinge RF, Kjekshus JK, Hall C. Cardiac 
natriuretic peptides and continuously monitored atrial pressures during 
chronic rapid pacing in pigs. Acta Physiol Scand. 2000;169:95–102 
 
66. Dokainish H, Pillai M, Murphy SA, et al. Prognostic implications of 
elevated troponin in patients with suspected acute coronary syndrome 
but no critical epicardial coronary disease: a TACTICS-
TIMCardiol.2005;45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
93 
 
 
 
 
PROFORMA 
 
NAME                                     AGE                                   SEX 
 
DATE OF ADMISSION                   
 
COMPLAINTS 
 
RELEVANT PRESENT HISTORY 
 
 
 
PAST HISTORY 
PREVIOUS EPISODE                                            
DIABETES                                                                                 
HYPERTENSION 
SMOKING  
ALCOHOL 
CAD 
DRUGS 
BP                                      PR 
GENERAL EXAMINATION 
CVS  EXAMINATION 
 
94 
 
 
 
 
 
INVESTIGATIONS  
ECG 
         1. 
         2. 
COMPLETE HEMOGRAM 
          
 
 
 
RENAL FUNCTION TEST 
 
 
 
 
ECHOCARDIOGRAM 
 
 
CK(MB) 
TROPONIN I 
CARDIOLOGY OPINION 
 
 
 
95 
 
 
 
 
 
TREATMENT GIVEN 
 
NAME AGE SEX WEIGHT
EPISOD
E
SMOKIN
G
ALCOH
OL
DIABET
ES
HYPERTEN
SION
             
HB ECG  ECHO   CK-MB Tn-i  sys BP DIA BP      LVH
ABDUL HAMEED    50    M 76 1 1 0 0 0 12 AVNRT N STUDY 3.6 1.08 160 90 1
AIYANAAR 72    M 72 2 1 0 0 1 8.4 AVNRT GRADE I DD   4.80 4.8 0.56 150 90 1
ALWYN 56    M 69 1 1 1 0 0 11 AVNRT N STUDY 0.08 0.12 108 46 0
ANTHONIAMMAL      56 F 43 1 0 0 0 0 7.8 AVNRT N STUDY 8.8 0.8 110 80 0
AROKYAMARY     62   F 90 1 0 0 1 1 8.8 AVNRT N STUDY 5.64 0.24 146 90 1
ARUMUGAM         68    M 68 1 1 0 0 0 8.8 AVNRT N STUDY 1.8 0.8 130 88 1
AZHAGARSAMY   58   M 68 1 1 1 1 1 11 AVNRT N STUDY 3.46 0.76 130 90 0
BABUNATHAN   43    M 88 1 1 0 0 0 12.8 AVNRT N STUDY 2.04 0.02 140 88 1
BATHRI 88    M 54 1 1 0 0 0 16 AVNRT N STUDY 8.88 0.98 126 88 0
CHANDRASINGH  58   M 88 1 1 0 0 0 11.8 AVNRT N STUDY 2.84 0.52 110 76 0
CHRISTOPHER   62  M 68 2 0 0 1 0 12 AVNRT N STUDY 2.76 0.42 150 70 0
CHRISTUDAS   48 M 92 1 0 1 0 0 13 AVNRT N STUDY 1.04 0.36 130 86 0
DANANJEYAN  37    M 89 1 1 1 0 1 14 AVNRT N STUDY 3.8 0.86 126 78 0
DAVID 54    M 78 1 1 1 0 0 9.8 AVNRT N STUDY 1.08 1.46 126 80 0
DENNY CLARIN  38  M 83 1 1 1 0 0 13.8 AVNRT N STUDY 1.26 0.08 120 80 0
DEVIKA                   68   F 76 2 0 0 1 1 9.2 AVNRT N STUDY 3.18 0.6 140 70 0
DEVISHREEE 40    F 58 1 1 0 1 0 8.8 AVNRT N STUDY 9 0.6 110 80 0
DHANASEKAR    56    M 76 1 0 0 1 1 9 AVNRT N STUDY 9 0.08 110 90 0
DINESH                22  M 56 1 0 0 0 0 12.2 AVNRT ATHLETE'S HEART 4 4 0.92 120 80 1
FATHIMA 65    F 49 1 0 0 1 1 13.6 AVNRT N STUDY 6.8 0.8 146 110 1
FEROZ KHAN     58 M 70 1 0 1 1 0 11 AVNRT N STUDY 3.8 0.98 112 88 0
GANESH       76    M 78 1 0 0 0 1 9.8 AVNRT N STUDY 6.8 0.98 130 88 1
GAYATHRI              30   F 52 4 0 0 0 0 9.8 AVRT WPW 2.03 0.48 100 68 0
GEETHA 64     F 46 1 0 0 1 1 9.8 AVNRT GRADE IDD      2.04 0.14 130 78 0
GEMINI 64    M 78 1 0 0 0 0 12 AVNRT N STUDY 2.08 1.14 112 86 0
GOVINDAMMAL  46   F 74 2 0 0 1 1 10.8 AVRT AV SCLEROSIS    4.8 4.8 0.78 110 90 0
GURU 53 M 90 1 1 1 1 0 11.6 AVNRT GRADE I DD   1.09 0.32 110 88 0
JAHARUL        56    M 78 1 1 1 0 0 13 AVNRT N STUDY 1.08 0.08 90 70 0
JAMES EDWARD 32  M 68 1 0 0 0 0 7.8 AVNRT MV PROLAPSE    5.04 5.04 0.2 130 72 0
KALAISELVI            28   F 76 1 0 0 0 0 12 AVRT WPW 3.48 0.46 98 80 0
KALAISELVI     72     F 86 1 0 0 0 1 6.8 AVNRT MILD AS                  1.04            0.3 1.04 0.3 160 60 1
KARTHIKEYAN    42 M 80 1 0 0 0 1 9.2 AVNRT N STUDY 2.06 0.72 126 90 0
KATHIRAVAN       48    M 46 1 0 0 1 0 10.8 AVNRT MV PROLAPSE    5.04 6.04 1.06 110 80 0
KRISHNAMOORHY 78 M 88 1 0 0 0 0 11 AVNRT N STUDY 8 1.6 130 90 1
KUMARI            46   F 78 1 0 0 1 1 9 AVNRT N STUDY 3.77 0.98 110 66 0
LAKSHMI 65    F 70 1 0 0 0 0 7.8 AVNRT N STUDY 3.78 0.98 100 80 0
MANGALAM      54   F 70 2 0 0 1 1 8.2 AVNRT N STUDY 3 0.46 180 90 1
MANGAMMAL     64   F 58 1 0 0 1 1 8.8 AVNRT N STUDY 2.6 0.16 110 78 0
MANI 48 M 80 2 1 1 0 0 12 AVNRT N STUDY 3.46 0.8 140 88 1
MANOJ         34   M 56 1 1 1 0 0 13.8 AVNRT N STUDY 5.2 0.88 108 70 0
MARIMUTHU 70    M 65 1 0 0 0 1 11 AVNRT N STUDY 5.68 1.08 142 88 1
MARY          64    F 68 1 0 0 1 0 9 AVNRT N STUDY 6.8 0.36 138 90 1
MUHAMED SIDIQ 56  M 75 1 1 1 1 0 11.8 AVNRT N STUDY 3.02 0.16 130 74 0
MURUGADOSS    78 M 68 1 1 1 1 1 7.8 AVNRT N STUDY 5.8 0.26 170 90 1
MURUGAMMAL  90    F 54 1 0 0 1 1 7.3 AVNRT GRADE 1 DD    10.08 0.8 80 60 0
MURUGESAN       65  M 68 1 1 1 1 1 5.6 AVRT WPW 3.08 0.67 106 66 0
NANDAKUMAR   86 M 45 1 1 1 0 1 4.8 AVRT GRADE III DD   2.06 0.08 108 70 0
NARASIMHAN     67    M 56 1 0 1 1 1 10.2 AVNRT GRADE I DD    7.06 0.16 150 78 1
NARMADA DEVI  66   M 90 1 0 0 1 0 11-Jan AVNRT GRADEIV DD    10.8 1.08 156 90 1
PARVATHI      54    F 86 1 0 0 1 1 9.8 AVNRT GRADE  II DD       5.6 5.6 0.28 170 102 1
POORNAM         73  F 65 1 0 0 0 0 11 AVNRT N STUDY 1.08 0.46 110 88 0
PRABHA                32    F 54 3 0 0 0 1 9.8 AVNRT N STUDY 0.06 0.04 110 80 0
RAJARATHINAM  62    M 90 1 0 1 0 1 10.8 AVNRT GRADE I DD            2.8 2.8 1.06 180 90 1
RAMANAIYA  56   M 76 1 1 1 0 1 11 AVNRT GRADE II DD 4.8 0.06 86 66 0
RAMESH BABU 49   M 68 1 1 1 0 1 13.2 AVNRT N STUDY 2.96 0.24 140 90 1
RATNAM 46    M 46 1 1 0 1 0 8.8 AVNRT AS 2.06 1.08 134 86 0
RAVANAMMAL   68   F 68 1 1 1 0 0 13.6 AVNRT GRADE I DD          4.800.36 4.8 0.34 130 90 1
RAVINDRAN   64    M 40 1 1 1 0 0 12.8 AVNRT N STUDY 4.8 0.8 156 98 1
SAMUVEL 63  M 72 1 1 0 1 0 10.4 AVNRT N STUDY 5.62 0.24 110 70 0
SAROJA 64   F 88 1 0 0 1 0 13.2 AVNRT GRADE 1 DD         4.90 4.9 2.8 180 90 1
SELVARAJ       63    M 66 1 0 0 0 0 11 AVNRTGRADE 1 DD         4.90             0.67 140/904.86 1.08 140 90 0
SINGARI 54   F 68 1 0 0 1 1 11 AVNRT N STUDY 1.06 0.68 170 80 1
SIVAGURU           52   M 88 1 1 0 1 1 11.6 AVNRT N STUDY 1.08 0.02 110 80 0
SIVAN 56    M 46 1 0 0 1 1 13 AVNRT N STUDY 3.08 0.48 130 90 0
SIVARAMAN  46    M 68 1 0 1 0 0 11.6 AVNRT GRADE II DD  5.6 0.06 66 40 0
SRIDHARAN           52  M 76 1 1 0 0 0 13 AVNRTGRADE II DD         4.96             0.92 120/804.98 0.92 120 80 0
STEPHEN             48   M 78 1 1 1 0 1 11.2 AVNRT N STUDY 4.26 0.04 136 88 0
SUGUNA 80   F 98 1 0 0 1 1 10.8 AVNRT AV SCLEROSIS    4.8 4.8 0.08 180 90 1
SULTHAN            66    M 78 1 1 0 1 1 11.8 AVNRT N STUDY 9.36 0.82 130 80 0
VINOTHINI 78    F 68 2 0 0 1 1 6.8 AVNRT N STUDY 0.46 0.08 110 80 0
SURESH 42   M 56 1 1 1 0 0 13.6 AVNRT N STUDY 4.29 0.16 110 80 0
THERESA 70    F 56 1 0 0 0 1 11 AVNRT GRADE 1 DD         2.08 2.08 0.02 118 80 0
VALLIAMMAL   45   F 69 1 0 0 1 1 9.8 AVNRT N STUDY 5.9 1.08 210 110 1
VEENA 14   F 45 1 0 0 0 0 11 AVNRT N STUDY 3.06 0.42 100 70 0
WILLIAMS         82    M 60 1 0 0 0 0 8.8 AVNRT GRADE II DD        10.2 10.2 2.02 136 88 1
0 - Absence of Risk factor
1 - Persence of Risk factor
 

 
